BioSpace News Archive

Mentice AB, a leading supplier of high-tech solutions for simulation in the medical sector, with a focus on endovascular procedures, announced the appointment of Pontus Appelqvist as Vice President and General Manager for Asia Pacific.

Exyte, world-renowned for the design and construction of high-tech facilities, has been awarded a fast-track project for Dexcom in Penang, Malaysia.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 clinical trial evaluating IDE397 (ClinicalTrials.gov Identifier: NCT04794699)

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will release first-quarter 2021 financial results before the market opens on Thursday, April 29, 2021, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

Kintor Pharmaceutical Limited (stock code 9939.HK, “Kintor Pharmaceutical” or the “Company”), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has received approval from the National Medical Products Administration to begin clinical trials for GT20029 (tincture/gel) for the treatment of acne and androgenetic alopecia.

Diamyd Medical has contracted the global contract research organization (CRO) ICON plc for DIAGNODE-3, a placebo-controlled Phase III precision medicine trial with the diabetes vaccine Diamyd®

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced interim data from Cohort 2 of its phase 2 EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis (RRMS).

Hoffmann-La Roche Limited (Roche Canada) today announced that Health Canada has granted EVRYSDIⓇ (risdiplam) market authorization for the treatment of spinal muscular atrophy (SMA) in patients two months of age or older.iii

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its gastroenterology (GI) business, Salix Pharmaceuticals (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today released a report of survey results that offers perspectives from U.S. adults living with irritable bowel syndrome (IBS) during the COVID-19 pandemic

Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne brand, completed an extensive rebranding effort in response to increased demand for its Assay Services offered at its Newark, CA laboratory.